Neurovascular devices company Rapid Medical revealed on Tuesday the receipt of US FDA clearance for the Comaneci device under the new temporary coil embolization assist devices category.
The company added that the Comaneci device, which is the first and only device in a new temporary coil embolization assist devices category, is the first-ever adjustable, fully-visible aneurysm remodelling device. It acts as a temporary bridge used to aid in the coiling processes while minimising the risk of coil protrusion or prolapse.
According to the company, the Comaneci device is the only temporary coiling assist device that does not require parent vessel occlusion during coiling procedure or the need for long-term antiplatelet medication in case of permanent stenting. It is the only non-vessel-occluding temporary intracranial coiling embolization assist device.
To date, the Comaneci have been successfully used in about 3,000 procedures outside the US, concluded the company.
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
MAP Medical agrees distribution deal with Metrix-Secure
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
Immuno Cure and PharmaJet collaborate for novel HIV therapeutic DNA vaccine advancement